33C

INNOCARE PHARMA LTD

Common Stock · EUR · F

33C

Price

€1.279

-3.62%

Cap

Earnings

30d Trend

-19.1%

33C
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

47% annualised over 90 days

BRAIN47 SIGNAL

0
MODERATE
Risk Level70
Quality42
Momentum56
Technical40
Fundamentals35

Raw weighted: 44×Macro 0.99 (1%)=44

RISK

70/100
90d Volatility
47.4%High
ATR %
3.1%High daily moves
Max Drawdown (1Y)
-45.8%Volatile

QUALITY

42/100
ROE (avg)
0.0%Weak
Piotroski F-Score
5/9Average
Accruals
-0.8%Cash earnings

MOMENTUM

56/100
12-1M Momentum
+17.6%Strong uptrend
6-1M Momentum
-8.1%Negative
1M Return
-12.6%Sharp decline

TECHNICAL

40/100
RSI (14)
33.3Neutral
Price vs SMA200
-17.5%Bearish trend
MACD
-0.01Bearish momentum
Bollinger Band
12%Near lower band
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.402Mixed

FUNDAMENTALS

35/100
P/S
7.4Fair

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months46
3-12 months37
1-5+ years41

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate INNOCARE PHARMA LTD at 44/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 56/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-12.6%

3 MONTHS

-1.6%

12 MONTHS

+5.0%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. Momentum (56) and Quality (42) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 47%. I classify this as a speculative position — elevated volatility at 47% and asymmetric payoff potential define the opportunity.

speculativeScore: 44/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.